Table 3 Treatment outcome among patients with uncomplicated malaria treated with Artemether–lumefantrine or Pyronaridine–artesunate in Ibadan, southwest Nigeria

TOTAL enrolled

87 (100)

85 (100)

172 (100)

Completed study

83 (95.4)

82 (96.5)

165 (95.9)

0.535

LTFU

3 (3.4)

2 (2.4)

5 (2.9)

Withdrawn

1 (1.2)

0 (0.0)

1 (0.6)

Withdrawal of consent

0 (0.0)

1 (1.2)

1 (0.6)

ITT-uncorrected

N = 87 (100)

N = 85 (100)

N = 172 (100)

ACPR—D28

59 (67.8)

76 (89.4)

135 (78.5)

0.001

Treatment failure

24 (27.6)

6 (7.1)

30 (17.4)

LTFU/withdrawn

4 (4.6)

3 (3.5)

7 (4.1)

PP—uncorrected

N = 83

N = 82

N = 165

ACPR—D21

73/83 (88.0)

82/83 (98.8)

135/166 (93.4)

0.016

ACPR—D28

59/83 (71.1)

76/82 (92.7)

135/165 (81.8)

LPF—D28

17 (20.5)

6 (7.3)

23 (13.9)

0.001

LCF—D28

7 (8.4)

0 (0.0)

7 (4.2)

PP-PCR corrected

N = 67

N = 78

N = 145

Cure rate—D28

59 (88.1)

76 (97.4)

135 (93.1

0.04

Recrudescence

8 (11.9)

2 (2.6)

9 (6.9)

Day of failure [N (%)]

24 (110)

6 (100)

30 (100)

Day 14

2 (8.3)

0 (0.0)

2 (6.7)

Day 21

9 (37.5)

1 (16.7)

10 (33.3)

0.405

Day 28

13 (54.2)

5 (83.3)

18 (60.0)

% Failed before D28

11 (45.8)

1 (16.7)

12 (40.0)

% Failed on D28

13 (54.2)

5 (83.3)

18 (60.0)

0.358

Parasite clearance time (days)

 Mean ± SD

2.15 ± 0.68

2.08 ± 0.64

2.12 ± 0.66

0.430

 Range

1–4

1–3

1–4

Fever clearance time (days)

 Mean ± SD

1.11 ± 0.32

1.13 ± 0.44

1.13 ± 0.38

0.664

 Range

1–2

1–3

1–3

Haematocrit at D28 (in %)

 Mean ± SD

33.3 ± 2.95

34.9 ± 2.79

34.13 ± 2.95

0.002

 Range

23–40

28–42

25–42

Haematocrit < 30% D28

1 (1.4)

1 (1.4)

2 (1.4)

1.000